CCL21 Enhances Platelet Activation and Atherothrombosis via CCR7 Activation
CCL21 enhances platelet activation and atherothrombosis by binding to platelet CCR7 and thus activating downstream Gi and G13 signaling pathways. A CCL21 antibody can counteract these effects in the context of coronary artery disease, supporting its potential as a preventive therapy for thrombotic complications.
Authors
- Yonghong Li (ORCID: https://orcid.org/0000-0002-1367-0092)
- Junjie Guo (ORCID: https://orcid.org/0009-0009-9449-0162)
- Xin Liu (ORCID: https://orcid.org/0000-0001-8429-5560)
- Peng Zhang
- Junbo Ge (ORCID: https://orcid.org/0000-0002-9360-7332)
- Zhiyong Qi (ORCID: https://orcid.org/0000-0001-5720-4061)
- Shimo Dai
- Ning Zhang
- Haichu Yu (ORCID: https://orcid.org/0009-0009-2516-454X)
- Zhexun Lia
Institutions
- Qingdao University (CN)
- Fudan University (CN)
- Affiliated Hospital of Qingdao University (CN)
Publication Details
- Journal
- Circulation Research
- Published
- 2025-10-10
- DOI
- https://doi.org/10.1161/circresaha.125.326784
- Citations
- 1
- Primary Topic
- Chemokine receptors and signaling
- Type
- article
- Field-Weighted Citation Impact
- 1.05